Barrett esophagus (BE) continues to be a major risk factor for developing esophageal adenocarcinoma.
Methods
We review the risk factors, diagnosis, and management of BE, with an emphasis on the most current endoscopic diagnostic modalities for BE.
Results
Novel diagnostic modalities have emerged to address the inadequacies of standard, untargeted biopsies, such as dye-based and virtual chromoendoscopy, endoscopic mucosal resection, molecular biomarkers, optical coherence tomography, confocal laser endomicroscopy, volumetric laser endomicroscopy, and endocytoscopy. Treatment of BE depends on the presence of intramucosal cancer or dysplasia, particularly high-grade dysplasia with or without visible mucosal lesions.
Conclusions
Recent advances in endoscopic diagnostic tools demonstrate promising results and help to mitigate the shortcomings of the Seattle protocol. Future research as well as refining these tools may help aid them in replacing standard untargeted biopsies.
References
1.
BarrettN.R.Chronic peptic ulcer of the oesophagus and ‘oesophagitis.’Br J Surg.1950; 38(150): 175–182.
2.
SpechlerS.J., SharmaP., SouzaR.F.American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett's esophagus.Gastroenterology.2011; 140(3): 1084–1091.
3.
LiuW., HahnH., OdzeR.D.Metaplasia esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium.Am J Gastroenterol.2009; 104(4): 816–824.
4.
WangK.K., Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.Am J Gastroenterol.2008; 103(3): 788–797.
5.
VelanovichV.Management of Barrett's esophagus.Am Surg.2012; 78(11): 1193–1200.
KuligM., NoconM., ViethM.Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study.J Clin Epidemiol.2004; 57(6): 580–589.
8.
KoekG.H., SifrimD., LerutT.Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus.Gut.2008; 57(8): 1056–1064.
9.
MarshallR.E., AnggiansahA.Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus.Br J Surg.1996; 83(3): 425–426.
10.
CaldwellM.T., LawlorP., ByrneP.J.Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus.Br J Surg.1995; 82(5): 657–660.
11.
ChampionG., RichterJ.E., VaeziM.F.Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus.Gastroenterology.1994; 107(3): 747–754.
12.
BealesI.L., VardiI., DearmanL.Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.Eur J Gastroenterol Hepatol.2012; 24(8): 917–923.
13.
KasteleinF., SpaanderM.C.W., BiermannK.Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.Gastroenterology.2011; 141(6): 2000–2008.
14.
SuZ., GayL.J., StrangeA.Esophageal Adenocarcinoma Genetics Consortium; Wellcome Trust Case Control Consortium 2. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus.Nat Genet.2012; 44(10): 1131–1136.
15.
ReidB.J.Barrett's esophagus and esophageal adenocarcinoma.Gastroenterol Clin North Am.1991; 20(4): 817–834.
16.
PolednakA.P.Trends in survival for both histologic types of esophageal cancer in US Surveillance, Epidemiology and End Results areas.Int J Cancer.2003; 105(1): 98–100.
17.
ZhangY.Epidemiology of esophageal cancer.World J Gastroenterol.2013; 19(34): 5598–5606.
18.
BultonR.A., UsselmannB., MohammedI.Barrett's esophagus: environmental influences in the progression of dysplasia.World J Surg.2003; 27(9): 1014–1017.
19.
LaveryD.L., NicholsonA.M., PoulsomR.The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands.Gut.2014; 63(12): 1854–1863.
YousefF., CardwellC., CantwellM.M.The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis.Am J Epidemiol.2008; 168(3): 237–249.
22.
LevineD.S.Management of dysplasia in the columnar-lined esophagus.Gastroenterol Clin North Am.1997; 26(3): 613–634.
23.
BorovickaJ., FischerJ., NeuweilerJ.Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.Endoscopy.2006; 38(9): 867–872.
24.
AbramsJ.A., KapelR.C., LindbergG.M.Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States.Clin Gastroenterol Hepatol.2009; 7(7): 736–742.
25.
EloubeidiM.A., ProvenzaleD.Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy.Am J Gastroenterol.1999; 94(4): 937–943.
26.
DulaiG.S.Surveying the case for surveillance.Gastroenterology.2002; 122(3): 820–823.
27.
StreitzJ.M.Jr, AndrewsC.W.Jr, EllisF.H.Jr. Endoscopic surveillance of Barrett's esophagus. Does it help?J Thorac Cardiovasc Surg.1993; 105(3): 383–388.
28.
CameronA.J., CarpenterH.A.Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.Am J Gastroenterol.1997; 92(4): 586–591.
29.
RayM.B., Mayfield-StokesS.Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a preliminary study.Gastrointest Endosc.2001; 54(3): 294–301.
30.
RagunathK., KrasnerN., RamanV.S.A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus.Endoscopy.2003; 25(12): 998–1003.
31.
NgamruengphongS., SharmaV.K., DasA.Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis.Gastrointest Endosc.2009; 69(6): 1021–1028.
32.
SturmM.B., WangT.D.Emerging optical methods for surveillance of Barrett's oesophagus.Gut.2015; 64(11): 1816–1823.
33.
Longcroft-WheatonG., DukuM., MeadR.Acetic acid spray is an effective tool for the endoscopic detection of neoplasia in patients with Barrett's esophagus.Clin Gastroenterol Hepatol.2010; 8(10): 843–847.
34.
TholoorS., BhattacharyyaR., TsagkournisO.Acetic acid chromoendoscopy in Barrett's esophagus surveillance is superior to the standard random biopsy protocol: results from a large cohort study.Gastrointest Endosc.2014; 80(3): 417–424.
35.
QumseyaB.J., WangH., BadieN.Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review.Clin Gastroenterol Hepatol.2013; 11(12): 1562–70.e1-2.
36.
GonoK., ObiT., YamaguchiM.Appearance of enhanced tissue features in narrow-band endoscopic imaging.J Biomed Opt.2004; 9(3): 568–577.
37.
GonoT., YamazakiK., DoguchiN.Endoscopic observation of tissue by narrowband illumination.Opt Rev.2003; 10(4): 211–215.
38.
MutoM., KatadaC., SanoY.Narrow band imaging: a new diagnostic approach to visualize angiogenesis in superficial neoplasia.Clin Gastroenterol Hepatol.2005; 3(7 suppl 1): S16–S20.
39.
WolfsenH.C., CrookJ.E., KrishnaM.Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus.Gastroenterology.2008; 135(1): 24–31.
40.
SharmaP., HawesR.H., BansalA.Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial.Gut.2013; 62(1): 15–21.
41.
ReyJ.W., KiesslichR., HoffmanA.New aspects of modern endoscopy.World J Gastrointest Endosc.2014; 6(8): 334–344.
42.
HoffmanA., KorcynskiO., TreschA.Acetic acid compared with i-scan imaging for detecting Barrett's esophagus: a randomized, comparative trial.Gastrointest Endosc.2014; 79(1): 46–54.
43.
HoffmanA., BastingN., GoetzM.High-definition endoscopy with i-Scan and Lugol's solution for more precise detection of mucosal breaks in patients with reflux symptoms.Endoscopy.2009; 41(2): 107–112.
44.
HoffmanA., SarF., GoetzM.High definition colonoscopy combined with i-Scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trial.Endoscopy.2010; 42(10): 827–833.
45.
HoffmanA., KagelC., GoetzM.Recognition and characterization of small colonic neoplasia with high-definition colonoscopy using i-Scan is as precise as chromoendoscopy.Dig Liver Dis.2010; 42(1): 45–50.
46.
[No authors listed]. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002.Gastrointest Endosc.2003; 58(6 suppl): S3–S43.
47.
CurversW.L., ten KateF.J., KrishnadathK.K.Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated.Am J Gastroenterol.2010; 105(7): 1523–1530.
48.
WaniS., AbramsJ., EdmundowiczS.A.Endoscopic mucosal resection results in change of histologic diagnosis in Barrett's esophagus patients with visible and flat neoplasia: a multicenter cohort study.Dig Dis Sci.2013; 58(6): 1703–1709.
49.
YoungP.E., GentryA.B., AcostaR.D.Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus.Clin Gastroenterol Hepatol.2010; 8(12): 1037–1041.
50.
di PietroM., BoerwinkelD.F., ShariffM.K.The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus.Gut.2015; 64(1): 49–56.
51.
Bird-LiebermanE.L., NevesA.A., Lao-SirieixP.Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus.Nat Med.2012; 18(2): 315–321.
52.
SturmM.B., PirakaC., ElmunzerB.J.In vivo molecular imaging of Barrett's esophagus with confocal laser endomicroscopy.Gastroenterology.2013; 145(1): 56–58.
FjimotoJ.G., PitrisC., BoppartS.A.Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy.Neoplasia.2000; 2(1-2): 9–25.
55.
SuterM.J., VakocB.J., YachimskiP.S.Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging.Gastrointest Endosc.2008; 68(4): 745–753.
56.
ZhouC., TsaiT., LeeH.Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos).Gastrointest Endosc.2012; 76(1): 32–40.
57.
IsenbergG., SivakM.V.Jr, ChakA.Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett's esophagus: a prospective, double-blinded study.Gastrointest Endosc.2005; 62(6): 825–831.
58.
EvansJ.A., PonerosJ.M., BoumaB.E.Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus.Clin Gastroenterol Hepatol.2006; 4(1): 38–43.
KiesslichR., GossnerL., GoetzM.In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy.Clin Gastroenterol Hepatol.2006; 4(8): 979–987.
61.
JohnsonE.A., De LeeR., AgniR.Probe-based confocal laser endomicroscopy to guide real-time endoscopic therapy in Barrett's esophagus with dysplasia.Case Rep Gastroenterol.2012; 6(2): 285–292.
62.
KondaV.J., ChennatJ.S., HartJ.Confocal laser endomicroscopy: potential in the management of Barrett's esophagus.Dis Esphagus.2010; 23(5): E21–E31.
63.
LeungK.K., MaruD., AbrahamS.Optical EMR: confocal endomicroscopy-targeted EMR of focal high-grade dysplasia in Barrett's esophagus.Gastrointest Endosc.2009; 69(1): 170–172.
64.
CantoM.I., AnandasabapathyS., BruggeW.Confocal Endomicroscopy for Barrett's Esophagus or Confocal Endomicroscopy for Barrett's Esophagus (CEBE) Trial Group. In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video).Gastrointest Endosc.2014; 79(2): 211–221.
65.
GuptaA., AttarB.M., KoduruP.Utility of confocal laser endomicroscopy in identifying high-grade dysplasia and adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol.2014; 26(4): 369–377.
66.
VakocB.J., ShishkoM., YunS.Comprehensive esophageal microscopy by using optical frequency-domain imaging (with video).Gastrointest Endosc.2007; 65(6): 898–905.
67.
SuterM.J., GoraM.J., LauwersG.Esophageal-guided biopsy with volumetric laser endomicroscopy and laser cautery marking: a pilot clinical study.Gastrointest Endosc.2014; 79(6): 886–896.
68.
EspnioA., CiroccoM., DacostaR.Advanced imaging technologies for the detection of dysplasia and early cancer in Barrett esophagus.Clin Endosc.2014; 47(1): 47–54.
ShaheenN.J., FrantzD.J.When to consider endoscopic ablation therapy for Barrett's esophagus.Curr Opin Gastroenterol.2010; 26(4): 361–366.
73.
GondrieJ.J., PouwR.E., SondermeijerC.M.Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system.Endoscopy.2008; 40(5): 370–379.
74.
PhoaK.N., van VilsterenF.G., WeustenB.L.Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial.JAMA.2014; 311(12): 1209–1217.
BirkmeyerJ.D., SiewersA.E., FinlaysonE.V.Hospital volume and surgical mortality in the United States.N Engl J Med.2002; 346(15): 1128–1137.
77.
BirkmeyerJ.D., StukelT.A., SiewersA.E.Surgeon volume and operative mortality in the United States.N Engl J Med.2003; 349(22): 2117–2127.
78.
GuardinoJ.M., KhandwalaF., LopezR.Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma.Am J Gastroenterol.2006; 101(10): 2187–2193.
79.
ChennatJ., KondaV.J., RossA.S.Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma–an American single-center experience.Am J Gastroenterol.2009; 104(11): 2684–2692.
80.
LarghiA., LightdaleC.J., RossA.S.Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.Endoscopy.2007; 39(12): 1086–1091.
81.
QumseyaB., PanossianA.M., RizkC.Predictors of esophageal stricture formation post endoscopic mucosal resection.Clin Endosc.2013; 47(2): 155–161.
82.
MannerH., RabensteinT., PechO.Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study).Endoscopy.2014; 46(1): 6–12.
83.
GanzR.A., UtleyD.S., StemR.A.Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus.Gastrointest Endosc.2004; 60(6): 1002–1010.
84.
FleischerD.E., SharmaV.K.Endoscopic ablation of Barrett's esophagus using the halo system.Dig Dis.2008; 26(4): 280–284.
85.
SchnellT.G., SontagS.J., ChejfecG.Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia.Gastroenterology.2001; 120(7): 1607–1619.
86.
HurC., ChoiS.E., RubensteinJH. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.Gastroenterology.2012; 143(3): 567–575.
87.
ShaheenN.J., SharmaP., OverholtB.F.Radiofrequency ablation in Barrett's esophagus with dysplasia.N Engl J Med.2009; 360(22): 2277–2288.
88.
WaniS., PuliS.R., ShaeenN.J.Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review.Am J Gastroenterol.2009; 104(2): 502–513.
89.
PouwR.E., WirthsK., EisendrathP.Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia.Clin Gastroenterol Hepatol.2010; 8(1): 23–29.
90.
Alvarez HerreroL., van VilsterenF.G., PouwR.E.Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm.Gastrointest Endosc.2011; 73(4): 682–690.
91.
DumotJ.A., VargoJ.J.2nd, FalkG.W.An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients.Gastrointest Endosc.2009; 70(4): 635–644.
92.
ShaheenN.J., GreenwaldB.D., PeeryA.F.Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia.Gastrointest Endosc.2010; 71(4): 680–685.
93.
JohnstonM.H., EastoneJ.A., HorwhatJ.D.Cryoablation of Barrett's esophagus: a pilot study.Gastrointest Endosc.2005; 62(6): 842–848.
94.
GosainS., MercerK., TwaddellW.S.Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results.Gastrointest Endosc.2013; 78(2): 260–265.
